Monoclonal therapies & novel mechanisms driving family hope and access [developing]

Korsana $175M BBB-penetrating anti-amyloid Ab via transferrin receptor, ARIA mitigation subQ trials 2027; lecanemab/LEQEMBI 27-30% subQ/AHEAD/UK MCI/no glymphatic/WashU cystatin/microglia/LBD blunts 40-55%; Toledo: Lewy co-path blunts trials/mAbs efficacy, stratify by pathology; real-world LEQEMBI MCI extension (Rob Kennedy story); donanemab MCI+LB; NeuroTherapia NTRX-07 Ph2a complete (oral microglia modulator safe PK+biomarkers/MRI/EEG AD signals); Cedars-Sinai stem-derived young immune cells reverse AD mouse mem/brain; NKGen/tau ASO/VNS/GLP-1/FLAV-27/Kobe mirror/BBB/AL001 LATTICE/FP802/DBS/AMBAR TPE 61-66% no ARIA/Bredesen; lithium orotate mice; cannabis microdose Ph2; pilose peptide SAMP8. Checklists/equity.